New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19PRNewsWire • 09/30/21
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19PRNewsWire • 09/29/21
FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical CancerPRNewsWire • 09/28/21
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Cantor Fitzgerald Virtual Global Healthcare 2021 Conference (Transcript)Seeking Alpha • 09/27/21
Regeneron (REGN) Antibody Cocktail REGEN-COV Gets WHO RecommendationZacks Investment Research • 09/27/21
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADVGlobeNewsWire • 09/21/21
New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADVPRNewsWire • 09/21/21
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Regeneron Oncology Investor Event, ESMO 2021 Conference (Transcript)Seeking Alpha • 09/20/21
ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLCPRNewsWire • 09/19/21